Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis

Arthritis Research and Therapy

Volumn 15, Issue 4, 2013, Pages

  Perosa, Federico ^a   Favoino, Elvira ^a   Cuomo, Giovanna ^b   Digiglio, Liboria ^a   Dammacco, Franco ^a   Prete, Marcella ^a   Valentini, Gabriele ^b   Racanelli, Vito ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

CENP A; disease activity index; FOXE 3; peptide; Systemic sclerosis

Indexed keywords

AP1 17 ANTIBODY; AP17 30 ANTIBODY; CENTROMERE ANTIBODY; CENTROMERE PROTEIN A ANTIBODY; FORKHEAD BOX PROTEIN E3; FORKHEAD TRANSCRIPTION FACTOR; FOXE3P53 62 ANTIBODY; IMMUNOGLOBULIN G; PEPTIDE ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; CENTROMERE PROTEIN A; EPITOPE; FOXE3 PROTEIN, HUMAN; NONHISTONE PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; BLOOD; CROSS REACTION; IMMUNOLOGY; LIMITED SCLERODERMA; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CHROMOSOMAL PROTEINS, NON-HISTONE; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNODOMINANT EPITOPES; MALE; RETROSPECTIVE STUDIES; ROC CURVE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC;

EID: 84880019880     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4249     Document Type: Article

References (45)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567. 10.1172/JCI31139, 1804347, 17332883.
2. Guy S, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008, 38:132-160. 10.1016/j.semarthrit.2007.10.010, 18221988.
3. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 2011, 10:267-275. 10.1016/j.autrev.2010.09.015, 20863909.
4. Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255. 10.1002/art.11073, 12905479.
5. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986, 13:911-916.
6. Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, Roussin A, Earnshaw W, Rothfield NF. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study. Arthritis Rheum 1991, 34:68-77. 10.1002/art.1780340111, 1845841.
7. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, Raymond Y, Senecal JL. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002, 81:154-167.
8. Earnshaw W, Bordwell B, Marino C, Rothfield N. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. J Clin Invest 1986, 77:426-430. 10.1172/JCI112320, 423362, 3511098.
9. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003, 5:80-93. 165038, 12718748.
10. Rattner JB, Rao A, Fritzler MJ, Valencia DW, Yen TJ. CENP-F is a.ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Moti Cytoskeleton 1993, 26:214-226.
11. Hsu TC, Chang CH, Lin MC, Liu ST, Yen TJ, Tsay GJ. Anti-CENP-H antibodies in patients with Sjogren's syndrome. Rheumatol Int 2006, 26:298-303. 10.1007/s00296-004-0568-4, 15700116.
12. Saito A, Muro Y, Sugiura K, Ikeno M, Yoda K, Tomita Y. CENP-O, a protein localized at the centromere throughout the cell cycle, is a novel target antigen in systemic sclerosis. J Rheumatol 2009, 36:781-786. 10.3899/jrheum.080726, 19286853.
13. Whyte J, Soriano E, Earnshaw WC, McHugh NJ. Frequency of autoantibodies to a major epitope on the carboxyl terminal fragment of CENP-B in patients with autoimmune disease. Br J Rheumatol 1995, 34:407-412. 10.1093/rheumatology/34.5.407, 7788167.
14. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005, 32:1488-1494.
15. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763. 10.1136/ard.2006.062901, 1954657, 17234652.
16. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010, 6:112-116. 10.1038/nrrheum.2009.238, 20125179.
17. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003, 48:203-209. 10.1002/art.10760, 12528120.
18. Perosa F, Vicenti C, Racanelli V, Leone P, Valentini G, Dammacco F. The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). Clin Immunol 2010, 137:60-73. 10.1016/j.clim.2010.06.008, 20630806.
19. Akbarali Y, Matousek-Ronck J, Hunt L, Staudt L, Reichlin M, Guthridge JM, James JA. Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies. J Autoimmun 2006, 27:272-280. 10.1016/j.jaut.2006.10.001, 1906738, 17210244.
20. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
21. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
22. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281-1285.
23. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985, 28:759-767. 10.1002/art.1780280706, 4015723.
24. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, Desai A, Seibold JR. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008, 35:458-465.
25. Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della RA, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003, 21:S42-S46.
26. Valentini G, Della RA, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, Cerinic MM, Belch JF, Black CM, Bruhlmann P, Czirjak L, De LA, Drosos AA, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Rosada M, Scorza R, Stork J, Sysa A, van den Hoogen FH, Vlachoyiannopoulos PJ. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001, 60:592-598. 10.1136/ard.60.6.592, 1753669, 11350848.
27. Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della RA, Silman AJ, Black CM, Czirjak L, Nielsen H, Vlachoyiannopoulos PG. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003, 62:901-903. 10.1136/ard.62.9.901, 1754649, 12922968.
28. Valentini G, Medsger TA, Silman AJ, Bombardieri S. Conclusion and identification of the core set of variables to be used in clinical investigations. Clin Exp 2003, 21:S47-S48. Rheumatol.
29. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003. 10.1056/NEJMra0806188, 19420368.
30. Doria A, Cutolo M, Ghirardello A, Zen M, Villalta D, Tincani A, Punzi L, Iaccarino L, Petri M. Effect of pregnancy on serum cytokines in SLE patients. Arthritis Res Ther 2012, 14:R66. 10.1186/ar3782, 3446434, 22417776.
31. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006, 107:1070-1077.
32. Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F. Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J Immunol 2007, 179:7967-7974.
33. Herzenberg LA, De Rosa SC, Dubs JG, Roederer M, Anderson MT, Ela SW, Deresinski SC, Herzenberg LA. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 1997, 94:1967-1972. 10.1073/pnas.94.5.1967, 20026, 9050888.
34. Hanke K, Becker MO, Brueckner CS, Meyer W, Janssen A, Schlumberger W, Hiepe F, Burmester GR, Riemekasten G. Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol 2010, 37:2548-2552. 10.3899/jrheum.100402, 20889593.
35. Koenig M, Dieude M, Senecal JL. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7:588-593. 10.1016/j.autrev.2008.06.010, 18617021.
36. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12:340-354. 10.1016/j.autrev.2012.05.011, 22743034.
37. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La MG, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002, 81:139-153.
38. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003, 42:534-540.
39. Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, Fritzler MJ. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 2012, 14:R50. 10.1186/ar3763, 3446416, 22394602.
40. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, Stevens W. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011, 13:R211. 10.1186/ar3544, 3334664, 22189167.
41. Hesselstrand R, Scheja A, Wuttge DM. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol 2012, 41:39-43. 10.3109/03009742.2011.610032, 22044051.
42. Bussone G, Tamby MC, Calzas C, Kherbeck N, Sahbatou Y, Sanson C, Ghazal K, Dib H, Weksler BB, Broussard C, Verrecchia F, Yaici A, Witko-Sarsat V, Simonneau G, Guillevin L, Humbert M, Mouthon L. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis 2012, 71:596-605. 10.1136/annrheumdis-2011-200195, 22084393.
43. Hudson M, Mahler M, Pope J, You D, Tatibouet S, Steele R, Baron M, Fritzler M. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012, 39:787-794.
44. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007, 6:432-437. 10.1016/j.autrev.2007.01.013, 17643929.
45. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009, 60:1112-1118. 10.1002/art.24409, 19333934.